Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 102 (11), 1071-1076

Current Evidence-Based Recommendations on Investigating Children With Global Developmental Delay


Current Evidence-Based Recommendations on Investigating Children With Global Developmental Delay

Renuka Mithyantha et al. Arch Dis Child.


Introduction: Global developmental delay (GDD) affects 1%-3% of the population of children under 5 years of age, making it one of the most common conditions presenting in paediatric clinics; causes are exogenous, genetic (non-metabolic) or genetic (metabolic). Recent advances in biotechnology and genetic testing mean that the investigations available to perform for children under 5 years are increasing and are more sensitive than previously. This change in availability and type of testing necessitates an update in the recommendations for investigating GDD.

Methods: We conducted a review of the literature from 2006 to 2016 to identify articles with evidence relating to the investigation of developmental delay in children under the age of 5 years. We collated the evidence into first-line and second-line investigations and, where available, on their yield and cost implications.

Results: We have provided up-to-date guidance for first-line and second-line investigations for children with GDD under the age of 5 years. Recent evidence demonstrates that genetic testing for all children with unexplained GDD should be first line, if an exogenous cause is not already established. Our review of the literature demonstrates that all patients, irrespective of severity of GDD, should have investigations for treatable conditions. Evidence demonstrates that the yield for treatable conditions is higher than previously thought and that investigations for these metabolic conditions should be considered as first line. Additional second-line investigations can be led by history, examination and developmental trajectories.

Discussion: We may need to update present recommendations in the UK for investigation of developmental delay. This would include microarray testing as first line and a more thorough approach to investigations for metabolic disorders that can be treated. Clinical assessment remains vital for guiding investigations.

Keywords: genetics; neurodevelopment; neurodisability.

Conflict of interest statement

Competing interests: None declared.


Figure 1
Figure 1
Flow chart for decision making for investigations for global developmental delay in young children.

Similar articles

See all similar articles

Cited by 5 articles


    1. Majnemer A, Shevell MI. Diagnostic yield of the neurologic assessment of the developmentally delayed child. J Pediatr 1995;127:193–9. 10.1016/S0022-3476(95)70294-6 - DOI - PubMed
    1. Shevell M, Ashwal S, Donley D, et al. Practice parameter: evaluation of the child with global developmental delay: report of the quality standards subcommittee of the american academy of neurology and the practice committee of the child neurology society. Neurology 2003;60:367–80. 10.1212/01.WNL.0000031431.81555.16 - DOI - PubMed
    1. Shevell MI, Majnemer A, Rosenbaum P, et al. Etiologic yield of subspecialists' evaluation of young children with global developmental delay. J Pediatr 2000;136:593–8. 10.1067/mpd.2000.104817 - DOI - PubMed
    1. Moeschler JB, Shevell M.Comprehensive evaluation of the child with intellectual disability or global developmental delays. Pediatrics 2014;134:e903–e918. 10.1542/peds.2014-1839 - DOI - PubMed
    1. Shonkoff JP, Hauser-Cram P. Early intervention for disabled infants and their families: a quantitative analysis. Pediatrics 1987;80:650–8. - PubMed